Comparing pharmacotherapy with pharmacotherapy and relaxation in migraine
Not Applicable
- Conditions
- Health Condition 1: G439- Migraine, unspecified
- Registration Number
- CTRI/2019/12/022538
- Lead Sponsor
- PGIMER
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Newly diagnosed migraine cases
Exclusion Criteria
Not willing to participate
Already on treatment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are targeted by pharmacotherapy in migraine management per CTRI/2019/12/022538?
How does relaxation therapy enhance standard pharmacotherapy for migraine-related disability improvement?
Which biomarkers correlate with response to combined pharmacotherapy and relaxation in CTRI/2019/12/022538?
What adverse events are associated with pharmacotherapy plus relaxation in migraine trials?
How do CGRP inhibitors compare to PGIMER's enhanced therapy approach in migraine quality-of-life outcomes?